Effects of extra virgin olive oil and regular olive oil on anthropometric, metabolic and inflammatory indices in patients with type 2 diabetes

Comparison of extra virgin olive oil and regular olive oil on anthropometric, metabolic and inflammatory indices in patients with type 2 diabetes: A three-arm randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250616066204N1

Enrollment

Registered

2025-06-29

Start date

2025-07-23

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: the first group (receiving 25 cc of extra virgin olive oil daily) and the next intervention group (receiving 25 cc of regular olive oil daily) will be for 8 weeks.

Eligibility

Sex/Gender

All

Age

45 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with an age range of 45 to 70 years Patients diagnosed with type 2 diabetes under drug therapy Serum glucose greater than 110 mg/dL Hemoglobin A1C maximum 7% Body mass index in the range of 25-30

Exclusion criteria

Exclusion criteria: Current consumption of alcohol History of kidney disease, kidney stones, digestive diseases, gallstones, and autoimmune diseases Using vitamin and mineral supplements, antioxidants, fiber supplements, omega-3 Taking insulin

Design outcomes

Primary

Measure	Time frame
Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.;Fasting blood sugar. Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;Glycosylated hemoglobin. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;C-Peptide. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;Body mass index. Timepoint: At the beginning of the study and three months later. Method of measurement: Centimeter and scales.;Waist. Timepoint: At the beginning of the study and three months later. Method of measurement: Centimeter.;Liver profiles (alkaline phosphatase, alanine transaminase, aspartate aminotransferase). Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.	—

Measure

Time frame

Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.;Fasting blood sugar. Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;Glycosylated hemoglobin. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;C-Peptide. Timepoint: At the beginning of the study and three months later. Method of measurement: ELISA device.;Body mass index. Timepoint: At the beginning of the study and three months later. Method of measurement: Centimeter and scales.;Waist. Timepoint: At the beginning of the study and three months later. Method of measurement: Centimeter.;Liver profiles (alkaline phosphatase, alanine transaminase, aspartate aminotransferase). Timepoint: At the beginning of the study and three months later. Method of measurement: BT2000 device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahnaz Joukar

Rasht University of Medical Sciences

farajov@gmail.com+98 13 3355 0028

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026